
Disclosures: Dr. Engert reports personal fees from Takeda/Millennium, personal fees from Affimed, personal fees from Novartis, outside the submitted work; Dr. Rodeghiero reports personal fees from Amgen, personal fees from GSK/Novartis, non-financial support from Celgene, non-financial support from Kedrion, outside the submitted work; Mr. Duyven? de Wit reports grants from BMS, grants from Celgene, grants from Novartis, grants from Takeda, grants from Janssen, grants from Roche, grants from AMGEN, grants from Gilead, grants from GSK, grants from ARIAD, grants from Alexion, grants from Shire, grants from AbbVie, grants from Vifor, grants from Infinity, grants from Pharmacyclics, grants from TEVA, grants from Sanofi/Genzyme, grants from Janssen, grants from Onyx, outside the submitted work; Ms. de Haas reports grants from BMS, grants from Celgene, grants from Novartis, grants from Takeda, grants from Janssen, grants from Roche, grants from AMGEN, grants from Gilead, grants from GSK, grants from ARIAD, grants from Alexion, grants from Shire, grants from AbbVie, grants from Vifor, grants from Infinity, grants from Pharmacyclics, grants from TEVA, grants from Sanofi/Genzyme, grants from Janssen, grants from Onyx, outside the submitted work; Dr. Hermine reports personal fees and other from AB science, grants from Novartis, grants from Celgene, grants and other from inatherys, grants from Theravectys, outside the submitted work; Dr. Vainchenker reports grants from Agence Nationale de la recherche, during the conduct of the study; grants from Sanofi, outside the submitted work; Dr. Barata reports personal fees from Novartis, outside the submitted work; Dr. Taghon reports grants from FWO, grants from IWT, grants from Ghent University, grants from Foundation against cancer, during the conduct of the study; Dr. Krause reports grants from LOEWE Center for Cell and Gene Therapy, during the conduct of the study; grants and personal fees from Glycomimetics Inc., personal fees from Novartis, personal fees from Bristol-Myers-Squibb, outside the submitted work; Dr. Mendez-Ferrer reports that he has no relevant real of apparent conflicts of interest. In addition, Dr. Mendez-Ferrer is an inventor of the following patent applications: Multipotent nestin-positive cells. PCT/ES/2010/070682, WO20110482 pending, a patent Neuro-regenerative/neurocompensatory therapy for the treatment of myeloproliferative neoplasms? and 'Compounds suitable for the treatment of myeloproliferative neoplasms as well as methods for the diagnosis/prognosis of myeloproliferative neoplasms'. Patent number: P201330677; PCT/EP2014/059678 pending, and a patent ?Selective estrogen receptor modulators for the treatment of myeloproliferative disorders?. Patent number: P9550ES00; PCT/ES2014/07041 pending,Dr. Mountford has a patent Erythroid Production pending, and a patent Stem Cell Culture Methods pending, Dr. MENENDEZ reports personal fees from European Food and Safety Authority, from null, during the conduct of the study; Dr. Tilly reports grants and personal fees from Celgene, personal fees and non-financial support from Roche, personal fees from Takeda, personal fees from Janssen, personal fees from Gilead, personal fees from Karyopharm, outside the submitted work; Dr. Aurer reports grants and personal fees from Roche, personal fees from Janssen, personal fees from Gilead, personal fees from Novartis outside the submitted work; Dr. Johnson reports grants from Janssen-Cilag, personal fees from Takeda, personal fees from Boeringher Ingelheim, grants from Epizyme, outside the submitted work; Dr. Vitolo reports personal fees from Roche, personal fees from Celgene, outside the submitted work; Dr. ribrag reports personal fees from servier, grants from bayer, personal fees from esai, grants from epizyme, personal fees from pharmamar, personal fees from infinity, grants from argen X, outside the submitted work; Dr. ribrag reports non-financial support from roche, personal fees from gilead, outside the submitted work; Dr. Dreyling reports grants from Celgene, Janssen, Mundipharma, Pfizer, Roche, personal fees from Bayer, Celgene, Gilead, Janssen, Mundipharma, Pfizer, Roche, outside the submitted work; Dr. Trneny reports grants and personal fees from ROCHE, grants and personal fees from CELGENE, personal fees from GILEAD, personal fees from AMGEN, personal fees from JANSSEN, personal fees from TAKEDA, outside the submitted work; Dr. Gribben reports personal fees from Roche/Genentech, personal fees from Celgene, personal fees from Janssen, personal fees from Pharmacyclics, personal fees from Gilead, personal fees from Acerta, personal fees from TG therapeutics, outside the submitted work; Dr. GAULARD reports personal fees from TAKEDA, outside the submitted work; Dr. Stilgenbauer reports grants and non-financial s...
Contributions: For each section in hematology, the Roadmap Task Force appointed one or two editors. Together, the Roadmap Task Force and section editors drafted and reviewed a more detailed framework of 60 “subsections” of groups of diseases and conditions. Section editors selected experts from their various fields to contribute as subsection editors or authors. Each section and subsection adapted the same basic format. Draft texts and figures were discussed by the Roadmap Task Force and section editors during three meetings between October 2014 and March 2015. After that, sections were reviewed by the Roadmap Task Force, the EHA board, and a selection of experts. The final draft was sent for consultation to stakeholders such as national hematology societies, patient organizations, hematology trial groups, and other European organizations in, for example, overlapping disease areas. All comments were discussed and integrated before submission of the manuscript to this peer-reviewed journal. In all, about 300 European hematologists and top experts were part of the generation of the Roadmap.